Toxic Effects of Endocrine Disruptor Exposure on Collagen-Induced Arthritis.
arthritis
endocrine disruptors
inflammation
oxidative stress
Journal
Biomolecules
ISSN: 2218-273X
Titre abrégé: Biomolecules
Pays: Switzerland
ID NLM: 101596414
Informations de publication
Date de publication:
10 04 2022
10 04 2022
Historique:
received:
11
03
2022
revised:
01
04
2022
accepted:
08
04
2022
entrez:
23
4
2022
pubmed:
24
4
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Endocrine disruptors (EDs) are chemical substances capable of affecting endocrine system functioning and interfering with organ morphogenesis and physiological functions. The development and regeneration of bone tissues have a complex hormonal regulation, and therefore, bone tissue cells can be considered potential targets for endocrine disruptors. In that regard, the aim of this research was to investigate the impact of ED exposure on the inflammatory response and oxidative stress in an experimental model of collagen-induced arthritis (CIA). Arthritis was induced by an emulsion of type II collagen (CII) and complete Freund's adjuvant, which was administered intradermally on days 0 and 21. Mice from day 21 to day 35 received the following EDs by oral gavage: cypermethrin (CP), diethyl phthalate (DEP), vinclozolin (VCZ), 17α-ethinylestradiol (EE), perfluorooctanesulfonic acid (PFOS) and atrazine (ATR). ED exposure caused worsening of clinical signs (erythema and edema in the hind paws), histological and radiographic changes, as well as behavioral deficits, induced by CII injections. Furthermore, ED exposure significantly increased the degree of inflammation and oxidative damage induced by arthritis; this upregulation was more evident after exposure to ATR than to other EDs. The results from our study suggest that exposure to EDs may play a deleterious role in the progression of RA; therefore, exposure to EDs should be limited.
Identifiants
pubmed: 35454153
pii: biom12040564
doi: 10.3390/biom12040564
pmc: PMC9025575
pii:
doi:
Substances chimiques
Collagen Type II
0
Endocrine Disruptors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Brain Behav Immun. 2007 May;21(4):384-92
pubmed: 17198749
Ann N Y Acad Sci. 2002 Jun;966:131-42
pubmed: 12114267
Sci Total Environ. 2014 Dec 1;500-501:191-8
pubmed: 25217994
Front Immunol. 2017 Jun 23;8:720
pubmed: 28690611
Arthritis Res Ther. 2016 May 5;18(1):101
pubmed: 27149951
Front Endocrinol (Lausanne). 2021 May 21;12:620920
pubmed: 34093428
Front Pharmacol. 2021 Mar 23;12:626107
pubmed: 33833678
Sci Rep. 2017 Sep 12;7(1):11353
pubmed: 28900117
Front Endocrinol (Lausanne). 2019 Mar 21;10:178
pubmed: 30984107
Allergy. 2006 Nov;61(11):1326-35
pubmed: 17002710
Antioxidants (Basel). 2020 Jul 09;9(7):
pubmed: 32660140
Nat Rev Immunol. 2007 Jun;7(6):429-42
pubmed: 17525752
Front Immunol. 2018 May 25;9:1165
pubmed: 29887869
EFSA J. 2018 Jul 27;16(7):e05383
pubmed: 32626004
PLoS One. 2015 Sep 24;10(9):e0139052
pubmed: 26402786
Biomed Pharmacother. 2020 May;125:110023
pubmed: 32092830
Data Brief. 2017 Jul 27;14:337-343
pubmed: 28795111
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3867-72
pubmed: 9520459
J Inflamm (Lond). 2015 Sep 15;12:53
pubmed: 26379475
Sci Total Environ. 2020 Mar 10;707:135945
pubmed: 31863984
Int J Mol Sci. 2020 May 15;21(10):
pubmed: 32429243
J Immunol. 2009 Jul 15;183(2):1328-36
pubmed: 19542367
Sovrem Tekhnologii Med. 2021;13(2):84-94
pubmed: 34513081
Immunol Rev. 1990 Dec;118:193-232
pubmed: 2079326
BMC Rheumatol. 2017 Nov 28;1:3
pubmed: 30886947
Anal Biochem. 1979 Jun;95(2):351-8
pubmed: 36810
Endocr Rev. 2015 Dec;36(6):E1-E150
pubmed: 26544531
Rev Endocr Metab Disord. 2020 Mar;21(1):117-125
pubmed: 31761961
Int J Mol Sci. 2020 Mar 20;21(6):
pubmed: 32244997
Int J Mol Sci. 2021 Apr 13;22(8):
pubmed: 33924467
Front Public Health. 2020 Sep 24;8:553850
pubmed: 33072697
J Environ Public Health. 2012;2012:713696
pubmed: 22991565
Biomed Res Int. 2014;2014:409837
pubmed: 24724082
Animals (Basel). 2020 Oct 08;10(10):
pubmed: 33049960
J Thromb Haemost. 2010 Aug;8(8):1838-46
pubmed: 20524981
Int J Mol Sci. 2020 Oct 18;21(20):
pubmed: 33080989
Basic Clin Pharmacol Toxicol. 2018 Jan;122(1):38-45
pubmed: 28842957
Amino Acids. 2021 Feb;53(2):171-181
pubmed: 33398523
Rev Endocr Metab Disord. 2020 Mar;21(1):127-147
pubmed: 31792807
Antioxidants (Basel). 2020 Jun 10;9(6):
pubmed: 32532064
Reprod Toxicol. 2012 Dec;34(4):694-707
pubmed: 23041264
J Pharmacol Exp Ther. 2011 Dec;339(3):859-69
pubmed: 21880869
Int J Mol Sci. 2021 Jul 26;22(15):
pubmed: 34360708
Amino Acids. 2022 Mar;54(3):433-440
pubmed: 35133468
Cell Physiol Biochem. 2021 Nov 18;55(6):704-725
pubmed: 34791862
Environ Toxicol Pharmacol. 2022 Jan;89:103779
pubmed: 34843942
PLoS One. 2009 Dec 02;4(12):e8127
pubmed: 19956573
Rev Endocr Metab Disord. 2015 Dec;16(4):269-70
pubmed: 26885651
Water Res. 2008 Feb;42(4-5):1133-41
pubmed: 17897695
Arthritis Res Ther. 2019 Dec 4;21(1):264
pubmed: 31801618
Mol Med Rep. 2015 Aug;12(2):2902-6
pubmed: 25955571
Biomed Res Int. 2014;2014:406453
pubmed: 25032213
Inflammopharmacology. 2020 Dec;28(6):1579-1597
pubmed: 32617791
Kaohsiung J Med Sci. 2012 Jul;28(7 Suppl):S37-42
pubmed: 22871600
Lancet Diabetes Endocrinol. 2020 Aug;8(8):719-730
pubmed: 32707119
J Neurochem. 2007 Mar;100(5):1177-87
pubmed: 17217422
Toxicol Rep. 2021 Jun 03;8:1193-1199
pubmed: 34150528
Endocrinology. 2012 Sep;153(9):4097-110
pubmed: 22733974
Antioxidants (Basel). 2020 Jul 24;9(8):
pubmed: 32722199
Pain Res Manag. 2018 Feb 7;2018:8564215
pubmed: 29623147